Andy Chen
Stock Analyst at Wolfe Research
(0.99)
# 3,518
Out of 4,829 analysts
34
Total ratings
29.17%
Success rate
-11.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $8.12 | +158.62% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $19.62 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $30.68 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $7.71 | - | 1 | Feb 4, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $20 | $9.54 | +109.64% | 1 | Feb 4, 2025 | |
| VERA Vera Therapeutics | Initiates: Outperform | $49 | $21.71 | +125.70% | 1 | Feb 4, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $19 | $9.06 | +109.71% | 1 | Feb 4, 2025 | |
| IMVT Immunovant | Downgrades: Peer Perform | n/a | $14.02 | - | 2 | Jan 3, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $697 | $549.27 | +26.90% | 2 | Nov 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Underperform | n/a | $251.15 | - | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $58.98 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $18.33 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $38.39 | - | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $30.07 | +116.16% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.85 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $299.69 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.39 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $0.75 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $32.30 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $35.62 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $10.64 | +59.77% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $424.99 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $65.08 | -35.46% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $0.69 | +8,659.12% | 1 | Aug 8, 2023 |
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $8.12
Upside: +158.62%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $19.62
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $30.68
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $7.71
Upside: -
Oruka Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $9.54
Upside: +109.64%
Vera Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $21.71
Upside: +125.70%
Zenas BioPharma
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $9.06
Upside: +109.71%
Immunovant
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $14.02
Upside: -
argenx SE
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $549.27
Upside: +26.90%
Alnylam Pharmaceuticals
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $251.15
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $58.98
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $18.33
Upside: -
Aug 26, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $38.39
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $30.07
Upside: +116.16%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $39.85
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $299.69
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $12.39
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $0.75
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $32.30
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $35.62
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $10.64
Upside: +59.77%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $424.99
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $65.08
Upside: -35.46%
Aug 8, 2023
Assumes: Buy
Price Target: $60
Current: $0.69
Upside: +8,659.12%